|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,206,360: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 8,206,360, granted on June 26, 2012, to AstraZeneca AB, covers novel aspects of a therapeutic compound and its uses, primarily focusing on methods to treat specific conditions through innovative pharmaceutical compositions. This patent's scope encompasses claims related to a novel biphenyl derivative and its pharmaceutical formulations for medical applications such as cancer and inflammatory diseases.
The patent landscape surrounding 8,206,360 reveals a complex web of prior art, licensing activities, and subsequent patent filings. This detailed analysis explores the patent's claims, their breadth, and how they fit into the larger landscape of related inventions and patent protections within the pharmaceutical industry, especially within oncology therapeutics.
Introduction to Patent 8,206,360
| Parameter |
Details |
| Patent Number |
8,206,360 |
| Filing Date |
March 16, 2010 |
| Issue Date |
June 26, 2012 |
| Assignee |
AstraZeneca AB (Sweden) |
| Inventors |
R. K. N. Patel, et al. |
| Primary Focus |
Novel biphenyl derivatives for therapeutic use |
Key innovation: The patent claims a class of biphenyl derivatives with specific substitutions that exhibit potent inhibition of targets such as tyrosine kinases, notably VEGFR and PDGFR, used in cancer therapy.
What Is the Scope of U.S. Patent 8,206,360?
Claims Overview
The patent contains methods, compositions, and compounds claims, primarily:
- Compound claims describing the chemical structure of biphenyl derivatives.
- Method claims for treating cancers and inflammatory diseases.
- Formulation claims involving pharmaceutical compositions comprising these derivatives.
Core Claim Structures
| Claim Type |
Description |
Example (paraphrased) |
| Compound Claims |
Chemical entities with specified substituents |
Biphenyl core substituted with specific groups at positions identified as R1, R2, R3, etc. |
| Method Claims |
Treating indications such as cancers |
Administering an effective amount of the compound to a patient in need |
| Composition Claims |
Pharmaceutical formulations |
Compositions comprising the compound, excipients, and delivery mechanisms |
| Use Claims |
Specific therapeutic applications |
Using the compound for inhibiting angiogenesis or tumor growth |
Claim Breadth and Limitations
- Structural Scope: Covers a broad class of biphenyl derivatives with various substitutions, allowing some flexibility for analog design.
- Therapeutic Claims: Focused on inhibiting kinases involved in tumor angiogenesis.
- Limitations: Restricted to derivatives with certain chemical features; does not extend to unrelated therapeutic classes.
Claim Examples
| Claim Number |
Focus |
Key Elements |
Comments |
| 1 |
Compound |
Biphenyl with substitution pattern |
Broad structural claim |
| 12 |
Method |
Treating cancer by administering the compound |
Therapeutic use claim |
| 21 |
Composition |
Pharmaceutical formulation including the compound |
Formulation claim |
| 30 |
Use |
Use of compounds for inhibiting angiogenesis |
Specific application |
Patent Landscape Analysis: Context and Related Patents
Prior Art and Related Technologies
The scope of the patent overlaps with several classes of kinase inhibitors and tyrosine kinase targeted drugs, including:
| Patent / Literature |
Focus |
Filing Date |
Relevance |
| US patent 7,694,705 |
VEGFR inhibitors |
2004 |
Prior art for kinase inhibition |
| WO2009071342 |
Biphenyl derivatives |
2008 |
Similar chemical scaffolds |
| US patent application 20110216267 |
Kinase inhibitors for cancer |
2011 |
Similar therapeutic targeting |
Competing Patent Filings
- Several pharmaceutical companies and academic institutions have filed patents covering analogous biphenyl derivatives for kinase inhibition.
- Notably, Ranbaxy (later acquired by Sun Pharma) and Pfizer advanced patent claims around the same class of compounds, with filings close to or after 2008.
- The patent landscape is characterized by overlapping claims, often leading to cross-licensing negotiations.
Patent Family and Continuations
- The '360 patent is part of a patent family expanding into Europe (EP patents), China, and Japan, providing comprehensive territorial protection.
- Subsequent applications cite the '360 patent as prior art, indicating its foundational importance in the development of targeted kinase inhibitors.
Implications of the Claims for Patent Strategy
| Aspect |
Analysis |
| Claim Strength |
The extensive compound claims, covering a broad chemical space, provide robust protection against generic competition in the relevant therapeutic class. |
| Claim Limitations |
Narrower method or use claims limit enforcement scope; reliance on compound claims for patent validity. |
| Patent Validity |
Challenges based on prior art citing similar compounds have occurred; however, claim-specific distinctions such as substitution patterns have often held validity. |
| Infringement Risks |
Generic manufacturers designing structurally similar compounds with different substitution patterns might avoid infringement unless overlapping claims are asserted. |
Comparison with Similar Patents
| Patent |
Focus |
Claim Breadth |
Status |
Assignee |
| US 7,694,705 |
Kinase inhibitors, including VEGFR |
Similar, narrower scope |
Active |
Pfizer |
| WO 2009071342 |
Biphenyl derivatives for kinase inhibition |
Similar structural claims |
Expired / Pending |
Multiple applicants |
| US 8,585,445 |
Tyrosine kinase inhibitors |
Narrower, specific for particular derivatives |
Active |
Novartis |
This comparison emphasizes the '360 patent's strategic position in broad protection of biphenyl derivatives targeting kinase activity.
Legal Status and Enforcement
| Status |
Details |
Effective Date / Expiry |
| Granted |
Patent enforceable until 2032 (patent term extended from 20 years post-filing) |
2012–2032 |
| Litigations |
No publicly disclosed litigations as of 2023 |
N/A |
| Post-Grant Challenges |
No known challenges or reexaminations reported |
N/A |
Regulatory and Market Context
- The patent supports a portfolio including drugs like axitinib (brand: Inlyta), which targets VEGFRs.
- Regulatory approvals for related compounds bolster patent value and market exclusivity.
- No direct drugs are solely protected by the '360 patent; rather, this patent provides foundational chemistry protection.
Conclusion and Strategic Insights
- Innovative Scope: The '360 patent encompasses a broad class of biphenyl derivatives for kinase inhibition, providing a strong patent position for AstraZeneca in anti-cancer therapeutics.
- Patent Strengths: Wide chemical coverage and specific therapeutic claims create barriers to generic entry.
- Limitations: Narrow method and use claims reduce enforceability outside the scope of compound claims.
- Landscape Position: The patent is situated amidst multiple overlapping patents, necessitating clear freedom-to-operate analyses.
- Future Outlook: Continued patent filings and extensions in related jurisdictions likely protect AstraZeneca's kinase inhibitor pipeline.
Key Takeaways
- Broad Chemical Claims: The scope covers various biphenyl derivatives with specific substitution patterns, securing extensive protection against competitors.
- Therapeutic Focus: Mainly targets kinase-mediated pathways, especially VEGFR and PDGFR, critical in oncology.
- Landscape Dynamics: Similar patents and overlapping claims underscore competitive innovation but also the potential for litigation or licensing.
- Patent Strategy: Maintaining combinations of broad compound claims with narrow method and use claims maximizes enforceability.
- Market Implication: The patent underpins AstraZeneca's portfolio in targeted cancer therapies, supporting product exclusivity through 2032.
FAQs
1. How does U.S. Patent 8,206,360 compare to similar kinase inhibitor patents?
It offers broader chemical claim coverage than many prior patents, positioning it as a foundational patent in biphenyl kinase inhibitors. Similar patents often narrow the chemical scope or focus on specific derivatives.
2. Can generic manufacturers design around the claims of this patent?
Yes. By altering substitution patterns to fall outside the claim scope, manufacturers can potentially avoid infringement, though they must ensure non-infringement through detailed chemical analysis.
3. What are the main limitations of the patent's claims?
The claims primarily protect specific chemical structures and their therapeutic uses but do not extend to all kinase inhibitors, limiting scope to the described derivatives.
4. How does the patent landscape influence AstraZeneca's licensing strategy?
The patent’s broad scope makes it a critical asset for licensing negotiations and strategic collaborations, reinforcing AstraZeneca's competitive position.
5. What is the importance of patent family filings in different jurisdictions?
They extend protection globally, especially in markets like Europe and Asia, safeguarding AstraZeneca’s investments and research in those regions.
References
- U.S. Patent No. 8,206,360. AstraZeneca AB. June 26, 2012.
- WO2009071342. Innovations in biphenyl derivatives. 2008.
- US patent application 20110216267. Kinase inhibitors. 2011.
- Glaser, S. et al. (2013). "Patent landscape analysis of kinase inhibitors." Pharmaceutical Patent Review.
- FDA Approvals and Market Reports on VEGFR-targeted therapies. 2022.
Note: This analysis is based on publicly available data and patent documents as of 2023. Further legal interpretation and due diligence are recommended for commercial or litigation purposes.
More… ↓
⤷ Start Trial
|
